| |
Evt/N
|
3yr-OS
|
95% CI
| |
|---|
|
All patients
|
|
PD-L1
| | | |
p = 0.0055
|
|
Negative (IC0)
|
4/38
|
89.4%
|
70.6–96.5
|
|
Positive (IC1/2/3)
|
9/28
|
57.4%
|
33.2–75.5
|
|
TILs
| | | |
p = 0.6312
|
|
0–10%
|
6/35
|
79.6%
|
57.0–91.2
|
|
> 10%
|
7/31
|
72.5%
|
50.6–85.9
|
|
TIM-3
| | | |
p = 0.0840
|
|
< 1%
|
2/21
|
93.8%
|
63.2–99.1
|
|
≥ 1%
|
11/45
|
67.0%
|
48.0–80.5
|
|
TIM-3
| | | |
p = 0.0274
|
|
0–4%
|
5/44
|
87.1%
|
68.6–95.1
|
|
≥ 5%
|
8/22
|
58.0%
|
33.1–76.4
|
|
LAG-3
| | | |
p = 0.7750
|
|
0
|
2/11
|
88.9%
|
43.3–98.4
|
|
> 0
|
11/55
|
73.5%
|
56.9–84.5
|
|
PD-L1 and TIM-3
| | | |
p = 0.0020
|
|
Others
|
7/54
|
84.6%
|
68.5–92.9
|
|
PD-L1+/TIM-3+
|
6/12
|
45.5%
|
16.7–70.7
|
|
No-pCR group
|
|
PD-L1
| | | |
p = 0.1186
|
|
Negative (IC0)
|
3/14
|
84.6%
|
51.2–95.9
|
|
Positive (IC1/2/3)
|
8/23
|
58.0%
|
33.0–76.5
|
|
TILs
| | | |
p = 0.8008
|
|
0–10%
|
5/16
|
72.0%
|
41.1–88.6
|
|
> 10%
|
6/21
|
65.7%
|
38.8–83.0
|
|
TIM-3
| | | |
p = 0.0702
|
|
0–4%
|
3/20
|
88.7%
|
61.4–97.1
|
|
≥ 5%
|
8/17
|
50.0%
|
24.5–71.0
|
|
PD-L1 and TIM-3
| | | |
p = 0.0479
|
|
Others
|
5/25
|
81.3%
|
57.3–92.6
|
|
PD-L1+/TIM-3+
|
6/12
|
45.5%
|
16.7–70.7
|
